Could PD-L1 positivity be associated with venous thrombosis in patients with non-small cell lung cancer?

[1]  A. M. Martin,et al.  Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group , 2022, Clinical and Translational Oncology.

[2]  Chunhua Ling,et al.  Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism , 2021, Cancer management and research.

[3]  F. Ghiringhelli,et al.  Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. , 2021, Thrombosis research.

[4]  Linxin Zheng,et al.  Venous thromboembolism in patients with severe lung cancer: a narrative review. , 2021, Annals of palliative medicine.

[5]  Jing Gao,et al.  PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway , 2021, Inflammation.

[6]  Xiaohan Qian,et al.  Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2021, Frontiers in Oncology.

[7]  P. Demelo-Rodríguez,et al.  Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review , 2021, International journal of molecular sciences.

[8]  H. Kenmotsu,et al.  Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study , 2021, Cancer medicine.

[9]  M. Preusser,et al.  Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. , 2020, Blood.

[10]  Dongsheng Xu,et al.  Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors , 2020, Biomarker Research.

[11]  Xuejun Guo,et al.  The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC , 2020, Respiratory Research.

[12]  C. Marosi,et al.  Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma , 2020, ESMO Open.

[13]  H. Borghaei,et al.  Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC) , 2019, Cancer.

[14]  G. Galli,et al.  Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients , 2019, Cancers.

[15]  H. Yao,et al.  Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer , 2019, JAMA network open.

[16]  M. Rebelatto,et al.  Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay , 2018, Diagnostic Pathology.

[17]  B. Branchford,et al.  The Role of Inflammation in Venous Thromboembolism , 2018, Front. Pediatr..

[18]  Jianying Zhou,et al.  Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study. , 2017, Journal of thoracic disease.

[19]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[20]  Xiandong Lin,et al.  Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer , 2017, Oncotarget.

[21]  M. Dolled-Filhart,et al.  Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[22]  C. Ay,et al.  Epidemiology and risk factors for venous thromboembolism in lung cancer , 2016, Current opinion in oncology.

[23]  N. Rezaei,et al.  Inflammation in venous thromboembolism: Cause or consequence? , 2015, International immunopharmacology.

[24]  Yi-long Wu,et al.  Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients , 2015, Supportive Care in Cancer.

[25]  Hisao Asamura,et al.  The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  L. Liang,et al.  Prevalence and associations of VTE in patients with newly diagnosed lung cancer. , 2014, Chest.

[27]  F. Guadagni,et al.  Clinical models and biochemical predictors of VTE in lung cancer , 2014, Cancer and Metastasis Reviews.

[28]  D. Soulières,et al.  Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study. , 2014, Thrombosis Research.

[29]  A. Khorana,et al.  Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States , 2013, Cancer.

[30]  A. Khorana,et al.  Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. , 2012, Lung cancer.

[31]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.